Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
December 13, 2022
Earlier this year, the IMF board approved the establishment of the Resilience and Sustainability Trust (RST) to provide financial support to countries addressing long-term structural challenges, including climate change and pandemic preparedness. 143 countries are eligible to receive support from th...
POLICY PAPERS
November 28, 2022
The experience of the COVID-19 pandemic—in the US and around the world—highlights the potential feasibility and importance of biomedical R&D for global health and welfare. Drawing from this experience and momentum, this paper argues that the US should deepen its engagement and ambition in global hea...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
POLICY PAPERS
November 15, 2022
Antimicrobial drugs form the backbone of modern medicine. Yet over time, use of these drugs selects for mutations that survive exposure to those same drugs, driving “antimicrobial resistance,” or AMR. In the absence of sufficient R&D investment for new antimicrobials, deaths from drug-resistant infe...
Blog Post
October 13, 2022
On this episode of Pandemic Proof, Dr. Ayoade Alakija, the World Health Organization’s Special Envoy for the Access to COVID-19 Tools Accelerator (ACT-A) and co-chair of the African Union’s African Vaccine Delivery Alliance, joins Javier Guzman to discuss global cooperation during health emergencies...
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
POLICY PAPERS
October 04, 2022
In this paper, we report the results of a horizon-scanning exercise to source opportunities for global health R&D investment—that is, high-value potential biomedical innovations which are currently underfunded but which could be transformative for health, quality of life, and health security in LMIC...
Blog Post
August 25, 2022
On this episode of Pandemic Proof from CGD, Dr. Boghuma Titanji, Assistant Professor of Medicine at the Emory University School of Medicine, joins Javier Guzman to reflect on the ongoing monkeypox outbreak and response. Together they discuss the parallels between monkeypox and previous infectious di...